Global CRISPR Technology Market To Reach $18.89 Billion By 2035

CRISPR technology market size was valued at $4.76 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 14.77% from 2026 to 2035. A primary macro driver accelerating market adoption is the rising global prevalence of inherited genetic conditions and complex chronic diseases, combined with strong government backing for advanced genomic medicine. According to public statistics from the National Human Genome Research Institute (NHGRI), federal research funding allocated for human genome editing programs reached $663.7 million in fiscal year 2025. Furthermore, statistical data from the U.S. Food and Drug Administration (FDA) confirms that over 100 investigational cell and gene therapy candidates utilizing CRISPR nucleases and base editors are currently in active clinical evaluation.

Browse the full report description of “CRISPR Technology Market Size, Share & Trends Analysis Report, By Product (Kits & Reagents, CRISPR Libraries, Enzymes, Design Tools, Other Products), By Technology (CRISPR/Cas9, CRISPR/Cas12, CRISPR/Cas13, CRISPR/Cpf1 (Cas12a), Other CRISPR Technologies), By Application (Genome Editing, Genetic Engineering, Disease Diagnosis, Drug Discovery & Development, Agricultural Biotechnology, Other Applications), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), Hospitals & Diagnostic Laboratories, Other End Users), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/crispr-technology-market

To expand commercial footprints, accelerate turnaround times, and secure technological leadership, major market participants have executed key strategic moves:

• Product Innovation & Analytical Expansion: Thermo Fisher Scientific introduced next-generation mass spectrometry and proteomics workflow solutions designed to streamline bioanalytical characterization and regulatory validation for complex gene editing modalities.
• Product Innovation & Clinical Breakthrough: Integrated DNA Technologies (IDT) and Aldevron (operating companies of Danaher Corporation) manufactured the world's first personalized in vivo mRNA-based CRISPR base-editing drug product in six months to treat an infant patient with a life-threatening inborn metabolic disorder.
• Geographical Expansion: The Department of Health – Abu Dhabi, in partnership with Vertex Pharmaceuticals and CRISPR Therapeutics, launched Casgevy in the United Arab Emirates, extending commercial gene editing access across the Middle East.
• Strategic Collaboration: Danaher Corporation established the Danaher-IGI Beacon for CRISPR Cures in partnership with the Innovative Genomics Institute (IGI) to develop standardized, scalable manufacturing technologies for rare disease gene editing therapeutics.
• Historic Regulatory Approval: CRISPR Therapeutics and Vertex Pharmaceuticals achieved historic U.S. FDA approval for Casgevy (exagamglogene autotemcel), the first CRISPR/Cas9 genome-edited therapy approved for sickle cell disease in patients 12 years and older.
• Portfolio Expansion: Merck KGaA expanded its global life science division's custom synthetic guide RNA (sgRNA) and CRISPR enzyme manufacturing capacity to meet growing global biopharmaceutical demand.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Competitive Landscape – Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Integrated DNA Technologies (IDT), CRISPR Therapeutics
• Key Questions Addressed by the Report
  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?
• Global CRISPR Technology Market Report Segment
  • By Product: Kits & Reagents, CRISPR Libraries, Enzymes, Design Tools, Other Products
  • By Technology: CRISPR/Cas9, CRISPR/Cas12, CRISPR/Cas13, CRISPR/Cpf1 (Cas12a), Other CRISPR Technologies
  • By Application: Genome Editing, Genetic Engineering, Disease Diagnosis, Drug Discovery & Development, Agricultural Biotechnology, Other Applications
  • By End User: Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), Hospitals & Diagnostic Laboratories, Other End Users

Global CRISPR Technology Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/crispr-technology-market